Earnings

HLS Therapeutics Q2 EPS $(0.03) Beats $(0.10) Estimate, Sales $14.673M Beat $14.467M Estimate

Aug 12, 2026 · 06:34 AM ET· updated 2h ago

HLS Therapeutics (TSX:HLS) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.10) by 70 percent. This is a 66.67 percent increase over losses of $(0.09) per share from the

Why It Matters

HLS Therapeutics lost less money than experts predicted this quarter, and also sold more products than expected. When a company doing better than people thought, it hints the business might be improving.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

MMM183.13

-0.00 (-0.00%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.